MediPoint: Renal Denervation - EU Analysis and Market Forecasts
(M2 PressWIRE Via Acquire Media NewsEdge) Dublin - Research and Markets (http://www.researchandmarkets.com/research/946fwr/medipoint_renal) has announced the addition of the "MediPoint: Renal Denervation - EU Analysis and Market Forecasts" report to their offering.
Numerous medical device news sources and industry executives have proclaimed renal denervation to be the top medical device breakthrough of the past two years, and for good reason. Hypertension is one of the most prevalent chronic conditions worldwide, with some studies estimating that 50% of the adult population globally will have the disease in the next 20 years.
With limited effectiveness from pharmacotherapy, medical device therapy has the potential for significant adoption in the treatment of resistive hypertension and uncontrolled hypertension, once efficacy and cost-effectiveness are proven. Additionally, the degree of blood pressure reduction found in long-term clinical trials from such a well-tolerated procedure has generated notable optimism about the intervention's application in other conditions where hyperactivity of the sympathetic nervous system plays a significant role, such as congestive heart failure.
This report and forecast focuses on the renal denervation market for these indications in the 5 major European markets, which include France, Germany, Italy, Spain, and the United Kingdom (UK).The EU was the first region where renal denervation was introduced, back in 2010. Since then, there has been very slow adoption of the procedure in the major European markets. The development of a brand new market comes with several hurdles, and these need to be overcome before any spikes in the procedure volumes can occur.
- An overview of renal denervation, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized EU renal denervation market revenue and future forecasts from 2010 to 2019.
- Investigation of current and future market competition for renal denervation
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the renal denervation sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as cardiovascular Surgeons
Best Medical International
Boston Scientific Corporation
Cordis Corporation and Johnson & Johnson
St. Jude Medical
For more information visit http://www.researchandmarkets.com/research/946fwr/medipoint_renal
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets,
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
Sector: Cardiovascular Devices (http://www.researchandmarkets.com/categories.asp?cat_id=233&campaign_id=946fwr)
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.com on the world wide web. Inquiries to email@example.com)).
(c) 2013 M2 COMMUNICATIONS
[ Back To Technology News's Homepage ]